Newly diagnosed endometrial carcinomas of the MMR-deficient molecular subtype research hub

Use of the Checkpoint inhibitor DOstarlimab in the endOmetrial cancer fertility-Sparing trEatment: CHOOSE study.

The CHOOSE study is looking at a new medicine called dostarlimab for women with newly diagnosed womb cancer. The goal is to see if this treatment can clear the cancer without needing surgery to remove the womb, helping patients keep their ability to have children in the future.